Skip to main content

Table 4 Bi-variate and multi-variate logistic regression analysis of patients on anti-thrombotic therapy at Cardiac Clinic, UOG hospital, Northwest Ethiopia, December 1, 2018 to September 30, 2019

From: Appropriate use of anti-thrombotic therapy in patients with atrial fibrillation at single-center experience, Northwest Ethiopia

Variable Anti-thrombotic therapy Appro. Inappro. COR (95%) P-value AOR (95%) P-Value
Stroke
 Yes 33 6 3.46 (1.37–8.70) 0.008 2.20 (0.56–8.70) 0.25
 No 105 66     
Type of AF
 Valvular 58 16 3.09 (1.58–6.07) 0.001 1.90 (0.80–4.80) 0.14
 Non-valvular 81 55     
INR monitoring
vCan afford 135 56 8.82 (2.80–27.72) < 0.001 2.60 (1.10–6.10) 0.001
 Can’t afford 4 15     
Heart failure
 Yes 124 66 0.8 (0.46–3.40) 0.67   
 No 14 6     
Hypertension   0.8 (0.73–3.0)    
 Yes 34 13   0.28   
 No 104 59     
Thyrotoxicosis
 Yes 19 19 0.45 (0.22–0.90) 0.026 0.80 (0.40–1.90) 0.67
 No 119 53     
Age (years)
  ≥ 75 15 3 2.80 (0.78–10.03) 0.13 2.20 (0.50–8.70) 0.25
  < 75 123 69     
Place of Residence
 Urban 68 34 1.08 (0.50–1.60) 0.77   
 Rural 70 38     
Formal education
 Yes 101 56 0.78 (0.60–2.50) 0.41   
 No 37 16     
  1. Note: AF atrial fibrillation, COR crude odds ratio, AOR adjusted odds ratio